Enlivex Therapeutics (NASDAQ:ENLV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Enlivex Therapeutics (NASDAQ:ENLV) from a sell rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

A number of other research analysts have also issued reports on the company. Zacks Research raised Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $247.50.

Enlivex Therapeutics Stock Down 5.2%

Shares of ENLV stock opened at $1.28 on Friday. The stock has a market capitalization of $22.39 million, a PE ratio of -0.16 and a beta of 1.60. Enlivex Therapeutics has a 52-week low of $1.15 and a 52-week high of $27.15. The stock’s 50-day moving average price is $4.25 and its 200 day moving average price is $10.29.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in shares of Enlivex Therapeutics in the 4th quarter valued at about $33,000. Invesco Ltd. purchased a new stake in Enlivex Therapeutics during the fourth quarter worth about $43,000. XTX Topco Ltd grew its position in Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after buying an additional 19,132 shares during the period. Jane Street Group LLC grew its position in Enlivex Therapeutics by 244.1% during the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after buying an additional 52,553 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in Enlivex Therapeutics during the third quarter worth about $57,000. 1.02% of the stock is owned by institutional investors and hedge funds.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.